These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1376431)

  • 1. Chemoprevention clinical trials.
    Kelloff GJ; Boone CW; Malone WF; Steele VE
    Mutat Res; 1992 Jun; 267(2):291-5. PubMed ID: 1376431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet RA; Doody LA; Malone WF; Hawk ET; Sigman CC
    J Cell Biochem Suppl; 1996; 26():1-28. PubMed ID: 9154166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention trials and surrogate end point biomarkers in the cervix.
    Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
    Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents.
    Singh DK; Lippman SM
    Oncology (Williston Park); 1998 Dec; 12(12):1787-800; discussion 1802, 1805. PubMed ID: 9874850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():55-62. PubMed ID: 7616753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for chemopreventive (anticarcinogenic) compounds in rodents.
    Boone CW; Steele VE; Kelloff GJ
    Mutat Res; 1992 Jun; 267(2):251-5. PubMed ID: 1376427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies.
    Alberts DS; Garcia DJ
    J Nutr; 1995 Mar; 125(3 Suppl):692S-697S. PubMed ID: 7884553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemopreventive drug development: perspectives and progress.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1994; 3(1):85-98. PubMed ID: 8118391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical evaluation of cancer prevention agents.
    Goodman GE
    Proc Soc Exp Biol Med; 1997 Nov; 216(2):253-9. PubMed ID: 9349694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of U.S. National Cancer Institute (USNCI) chemoprevention research.
    Johnson KA; Ford LG; Kramer B; Greenwald P
    Acta Oncol; 1994; 33(1):5-11. PubMed ID: 8142125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
    Parnes HL; House MG; Kagan J; Kausal DJ; Lieberman R
    J Urol; 2004 Feb; 171(2 Pt 2):S68-74; discussion S75. PubMed ID: 14713758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The retinoids and cancer prevention mechanisms.
    Dragnev KH; Rigas JR; Dmitrovsky E
    Oncologist; 2000; 5(5):361-8. PubMed ID: 11040271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview.
    Crowell JA
    Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of cancer--focusing on clinical trials.
    Kakizoe T
    Jpn J Clin Oncol; 2003 Sep; 33(9):421-42. PubMed ID: 14594936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition).
    Gray J; Mao JT; Szabo E; Kelley M; Kurie J; Bepler G;
    Chest; 2007 Sep; 132(3 Suppl):56S-68S. PubMed ID: 17873160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of cancer.
    Szarka CE; Grana G; Engstrom PF
    Curr Probl Cancer; 1994; 18(1):6-79. PubMed ID: 8005001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.